tiprankstipranks
Trending News
More News >

Xinhua Pharmaceutical Gains Approval for Marketing License Transfer

Story Highlights
Xinhua Pharmaceutical Gains Approval for Marketing License Transfer

Don’t Miss TipRanks’ Half-Year Sale

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an update.

Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder for its Avatrombopag Maleate Tablets. This approval follows a transfer agreement with Shanghai Desenuo Pharmaceutical Group, which includes the transfer of all related technical ownership rights to Xinhua Pharmaceutical. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and operational capabilities in the pharmaceutical sector.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited operates in the pharmaceutical industry, focusing on the production and marketing of prescription drugs. The company is based in the People’s Republic of China and is involved in the development and commercialization of pharmaceutical products, including Avatrombopag Maleate Tablets.

Average Trading Volume: 4,889,496

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.26B

See more data about 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1